Effects of Thyroid Hormones on the Organism

#### **Chapter 2**

## Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System

*Volkan Gelen, Emin Şengül and Abdulsamed Kükürt*

#### **Abstract**

Thyroid hormones (thyroxine, triiodothyronine) have a metabolic effect on many tissues and systems in the organism. Therefore, in case of deficiency or excess of these hormones, some problems arise. The decrease in the effect of these hormones in the peripheral target tissue is called hypothyroidism, the picture characterized by excessive secretion of the thyroid gland or being of non-thyroid origin is called hyperthyroidism. Thyroid hormone disorders are common in the world. Knowing the functions of thyroid hormones, which have such important effects on the organism, is important in developing treatment options for the problems to be encountered. In the literature reviews, it has been stated that thyroid hormones have some effects such as heart rate, myocyte contraction, blood pressure, plasma lipid level, and thrombogenesis. In line with this information, the presented section has tried to explain how the mechanism of the effects of thyroid hormones on the cardiovascular system.

**Keywords:** TSH, T4, T3, hyperlipidemia, thrombogenesis, blood pressure

#### **1. Introduction**

The thyroid gland, which is the largest of the endocrine glands and is located in the right and left lobes on both sides of the end of the larynx and the beginning of the trachea, is histologically composed of many spherical follicles. The space in the middle of the follicle surrounded by a single layer of epithelial cells is filled with a substance called colloid. The main substance of the colloid is a large glycoprotein, namely thyroglobulin, which also contains the gland hormones like thyroxine (T4) and triiodothyronine (T3) [1]. These hormones are secreted as a result of stimulation of the thyroid gland by the thyroid-stimulating hormone (TSH) released from the pituitary [2]. The thyroid gland shows its effects on the target tissue through these two hormones. Of these hormones, T3 has a much stronger effect than T4. T4 is converted to T3 by monodeiodinization in the periphery [3]. T3 exerts its effects at nuclear and nonnuclear levels. Its effects at the nuclear level are through the regulation of gene expression [4]. These hormones released from the thyroid gland affect metabolic processes in almost all tissues [5–8]. Insufficient or excessive secretion of these hormones causes many problems in the organism. As a result of various studies, it has been reported that the effects of thyroid hormones on the cardiovascular system are very important

and prominent [9]. It shows this effect in two ways: direct and indirect. In line with this information, in the presented section, the synthesis of thyroid hormones, their mechanisms of action, and their effects on the cardiovascular system and the mechanism of these effects will be discussed.

#### **2. Thyroid hormones**

Thyroid hormones are thyroxine (T4) and 3,5,3′ triiodothyronine (T3) and these hormones are released into the blood by being released from the thyroid gland. These hormones are very important for normal growth and development and the normal functioning of metabolism. In addition to these hormones, the calcitonin hormone, which is involved in Ca metabolism, is also released from parafollicular C cells in the thyroid gland [7].

#### **2.1 Synthesis of thyroid hormones**

The release of thyroid hormones from the thyroid gland is under the control of the TRH hormone released from the hypothalamus. TRH released from the hypothalamus stimulates the pituitary gland to release TSH. TSH released from the pituitary stimulates the thyroid gland and ensures the release of hormones from here [10]. Thyroid hormones are attached to the thyroglobulin molecule in the thyroid gland. These hormones, which are stored in the thyroid gland, are given to the blood circulation when needed. In general, the synthesis of thyroid hormones consists of 5 stages. These stages are as follows, in order: (1) uptake of iodine ion into the gland, (2) oxidation of iodine and iodination of the tyrosyl groups of thyroglobulin, (3) coupling of iodotyrosine residues with ether bonds (coupling) to form iodothyronines, (4) proteolysis of thyroglobulin and thyroxine (T4). Release of T3) into the blood, (5) conversion of thyroxine to triiodothyronine in both the thyroid gland and peripheral tissues [7, 11]. When the T3 and T4 hormones released into the blood under the control of these hormones reach a certain level, they stop the release by having a feedback effect on the hypothalamus and pituitary gland [12].

Although T3, one of the thyroid hormones, is released from the thyroid gland, the source of 80% of the circulating T3 is T3, which is formed as a result of the metabolism of T4 in peripheral tissues. The enzyme that provides the transformation in question is iodothyronine-5′-deiodinase. The place where the transformation takes place the most is the liver. The source of T3 used in many peripheral tissues is the hormone released as a result of this transformation. Unlike these tissues, locally synthesized T3 is used in the brain and pituitary gland. When thyroid hormones are released into the blood, they are transported in the blood by noncovalent binding to plasma proteins. At the beginning of these transporters is thyroxine-binding globulin (TBG). T4 binds to this binder with high affinity, whereas T3 has less affinity. T4 also binds to transthyretin (transthyretin: thyroxine-binding prealbumin) (**Figure 1**) [7, 13, 14].

#### **2.2 Mechanism of action of thyroid hormones**

Considering the mechanisms of action of thyroid hormones in the cell, T3 is clamped to high-affinity nuclear receptors on the cell surface, which then binds to a specific DNA sequence (thyroid hormone response element: TRE) in the promoter/ regulatory regions of specific genes. In this way, T3 modulates gene transcription and ultimately protein synthesis. The binding of T3 to the receptor can activate gene *Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System DOI: http://dx.doi.org/10.5772/intechopen.109623*

**Figure 1.** *Control of synthesis of thyroid hormones [7].*

#### **Figure 2.**

*Mechanism of action of thyroid hormones on target cell [7].*

transcription by removing suppression. The interaction of hormones with their receptors can cause direct stimulating or suppressive effects. Although T4 also binds to the aforementioned receptors, it shows less affinity than T3. In addition, despite its ability to bind to nuclear receptors, T4 does not have a gene transcription-modifying effect [15]. Therefore, T4 appears to be more of a prohormone, and the effects of TH are considered to be mainly through T3 [16]. TH also exerts some of its effects on receptors in mitochondria. These hormones increase the oxidative metabolism of mitochondria, oxygen consumption, and ATP formation in some cell types (**Figure 2**) [17, 18].

#### **3. Effects of thyroid hormones on the cardiovascular system**

Thyroid hormone (TH) receptors (TRs) are located in the myocardium and vascular endothelium, so changes in circulating TH concentration have an effect on cardiac and vascular functions. In patients with hypo- or hyperthyroidism, cardiovascular (CV) and hematological manifestations occur. Minor changes in TH concentration may have an adverse effect on the CV system, and subclinical thyroid dysfunction may result in a 20–80% increase in the risk of vascular morbidity and mortality [19, 20, 21].

#### **3.1 Thyroid hormone and heart rate**

Heart rate is an important mechanism in the regulation of the cardiac output, which specifically determines the cardiac ejection rate. It also affects systolic and diastolic functions [22]. Considering the relationship between thyroid hormone and heart rate, studies have shown that thyroid hormone has a consistent positive chronotropic effect and causes resting sinus tachycardia [23].

#### **3.2 Effect of thyroid hormones on cardiac myocytes**

The genomic effects of TH are mediated by TH nuclear receptors in the cell. Protein receptors bind to T3 with more than 10-fold greater affinity than T4 [24]. In mammals, there are two isoforms of these receptor proteins, a and b (TRa and TRB). TRa and TRB activate the expression of positively regulated genes in the presence of T3 and suppress expression in their absence. It has been determined that the TRa1 isoform plays an important role in the regulation of cardiac genes. It contains myosin heavy chain an (a-MHC) and myosin heavy chain b (b-MHC) as contractile apparatus of cardiac myocytes. The fast myosin a-MHC and the slow myosin b-MHC are positively and negatively regulated by T3. Cardiac contractility is further regulated by several important cardiac proteins, including sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA2) and its inhibitory counterpart, phospholamban (PLB). SERCA2 functions to pump calcium (Ca2+) ions back into the sarcoplasmic reticulum during the relaxation phase of myofilament contraction. T3 positively regulates SERCA2 while negatively regulating PLB. SERCA2 and PLB are responsible for calcium ion influx into the sarcoplasmic reticulum and subsequent release [25]. Decreased calcium turnover in cardiac myocytes has been reported in hypothyroidism with impaired diastolic function. Other important cardiac genes regulated by TH include those encoding TR proteins themselves, voltage-gated potassium ion (K+) channels, and sodium/calcium ion (Naþ/Ca2+) exchanger (NCX1).TH (both T4 and T3) exerts non-genomic effects on cardiac myocytes and vessels. Non-genomic effects usually occur at the receptorindependent plasma membrane and regulate ion transporter activity [26]. These combined mechanisms at the atrial myocyte level are partly responsible for the heart rate-enhancing effect of T3 [27].

*Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System DOI: http://dx.doi.org/10.5772/intechopen.109623*

#### **3.3 Effect of thyroid hormones on vascular**

When the effects of TH on the vessels are examined, it is seen that the effect occurs at the vascular smooth muscle and endothelial cell levels. TH acts through ion channel activation (Na+, K+, Ca2+) and regulation of specific signal transduction pathways. It also activates the phosphatidylinositol 3-kinase and serine/threonine protein kinase pathways, resulting in nitric oxide production from the endothelium. Thus, it causes a decrease in systemic vascular resistance through its effects on vascular smooth muscle cells [28]. Some studies have shown that TH regulates endothelial nitric oxide production and vascular tone, and patients with hypothyroidism exhibit impaired endothelial function, which is improved by TH replacement therapy [29–31]. In addition, T3 may produce a vasodilator effect within hours after the application in patients undergoing coronary artery bypass grafting [32]. Similar effects are observed when patients with chronic heart failure are treated with intravenous T3 [33]. T3, therefore, has the unique pharmacological properties of an indicator acting primarily on diastolic dysfunction. TH does not have vasodilator effects in the pulmonary vasculature or systemic vasculature [34].

#### **3.4 Cardioprotective effect of thyroid hormones**

THs are involved in cardioprotection through the activation of cytoprotective mechanisms, stimulation of cell growth, neoangiogenesis, and metabolic adaptation. Recent experimental studies using the ischemia/reperfusion rat model have shown that TH has multiple protective effects, particularly on mitochondria. TH is a regulator of the tumor suppressor p53, which is activated during acute myocardial infarction (AMI) and enhances the mitochondrial apoptosis pathway [35]. This promotes p53 accumulation and, therefore, increases mitochondrial dysfunction and BCL-2-like protein 4 activation, leading to the prolongation of myocardial cell loss [36]. T3 treatment counteracts the reduction in miR-30a levels, thereby limiting p53 activation and the cascade that leads to mitochondrial damage and cell death in the AMI border region [37]. In addition, T3 treatment preserves the expression of hypoxia-inducible factor 1-alpha, whose protective effect against reperfusion injury is mediated by inhibiting the mitochondrial opening of permeability passage pores [38]. THs have an antiapoptotic effect on myocytes through activation of phosphatidylinositol 3-kinase/serine/threonine protein kinase and protein kinase C signaling cascades, expression, phosphorylation and translocation of heat shock proteins 70 and 27, and suppression of p38 mitogen [39].

#### **3.5 Thyroid hormones and blood pressure**

Considering the effects of hyperthyroidism on blood pressure, it causes hyperdynamic circulation, which causes an increase in cardiac contractility and thus increases heart rate, again with increased preload and decreased systemic vascular resistance (SVR). As a result, cardiac output increases. Although hyperthyroidism can increase systolic blood pressure, the net effect depends on the balance between increased cardiac output and decreased SVR [40, 41]. Endothelium-dependent vasodilation is lower in patients with severe hypothyroidism and SCH [42] and improves with levothyroxine therapy, as is the pulse-wave rate [43, 44], a surrogate measure of arterial stiffness. Various factors possibly contribute to arterial stiffness and endothelial dysfunction in SCH and hypothyroidism, including hyperlipidemia and a proinflammatory state [45–47]. Both hyperlipidemia and thyroid antibodies are thought to reduce endothelial nitric oxide synthase expression and thus impair vasodilation.

#### **3.6 Thyroid hormones and hyperlipidemia**

Hyperthyroidism lowers cholesterol levels, which reverses when euthyroidism is reached. Hypothyroidism is associated with a small but significant increase in lipid parameters [38], particularly the elevation of low-density lipoproteins (LDLs) [48]. Hypothyroidism is associated with increased oxidation of LDL, which promotes atherogenesis and improves with treatment [49, 50]. Lipoprotein(a), a stronger marker of atherogenesis, is also increased in overt hypothyroidism and decreased with TH replacement [51, 52]. In hypothyroidism, hyperlipidemia results from a decrease in LDL receptors, resulting in decreased cholesterol clearance from the liver and decreased cholesterol-clearing activity of cholesterol 7α-hydroxylase activated by TH [48]. In addition, thyroid hormones stimulate lipoprotein lipase (LPL), which catabolizes TG-rich lipoproteins, and hepatic lipase (HL), which hydrolyses HDL2 to HDL3 and contributes to the conversion of medium-density lipoproteins (IDL) to LDL. Another effect of T3 is the up-regulation of apolipoprotein AV (ApoAV), which plays an important role in TG regulation. In studies, this situation has been associated with increased ApoAV levels and decreased TG levels.

#### **3.7 Thyroid hormones and thrombogenesis**

Overt and SHyper have been associated with increased markers of thrombogenesis (fibrinogen and factor X levels) [53, 54]. Hyperthyroid patients may have higher von Willebrand antigen levels than euthyroid patients, resulting in increased platelet plug formation, decreasing after treatment [55]. Interestingly, a study comparing patients with moderate and severe hypothyroidism with euthyroid controls found that patients with moderate hypothyroidism had reduced fibrinolytic activity and were more susceptible to clot formation, while patients with severe hypothyroidism had increased fibrinolysis and lower tissue plasminogen activator antigen [56]. The effects of TH on platelet function are unclear [55].

#### **4. Conclusion**

In conclusion, this section presents the importance of thyroid hormones for the organism and the synthesis steps of these hormones, their transport in the blood, and their effects on the cardiovascular system. The mechanisms of these effects are discussed by reviewing the current literature. This study aims to present current literature information to researchers who will work on this subject.

*Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System DOI: http://dx.doi.org/10.5772/intechopen.109623*

#### **Author details**

Volkan Gelen1 \*, Emin Şengül<sup>2</sup> and Abdulsamed Kükürt3

1 Faculty of Veterinary Medicine, Department of Physiology, Kafkas University, Kars, Turkey

2 Faculty of Veterinary Medicine, Department of Physiology, Atatürk University, Erzurum, Turkey

3 Faculty of Veterinary Medicine, Department of Biochemistry, Kafkas University, Kars, Turkey

\*Address all correspondence to: gelen\_volkan@hotmail.com

© 2023 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### **References**

[1] Emirzeoğlu M, ve Sancak, R. Tiroit bezi anatomisi. Journal of Experimental and Clinical Medicine. 2012;**29**(4S):273-275

[2] Bostancı N. Paratiroid Hastalıkları. Bozak Matbaası: İstanbul; 1979. pp. 199-248

[3] Cooper DS. Hyperthyroidism. The Lancet. 2003;**362**:459-468

[4] Parry C. Palpitation of the heart in connection with enlargement of the thyroid. Disease Heart. 1825;**2**:111-165

[5] Osman F, Gammage MD, Franklyn JA. Thyroid disease and its treatment: Short-term and long-term cardiovascular consequences. Current Opinion in Pharmacology. 2001;**1**:626-631

[6] Keçeci T, ve Kocabatmaz M. Hipotiroidizmin kan üre azotu, total protein, glikoz ve total kolesterol düzeyleri üzerindeki etkisi. Veteriner Bilimler Dergisi 1994;**10**(1-2):134-138

[7] Hall JE. Guyton and Hall Textbook of Medical Physiology Elsevier Health Sciences. USA: Elsevıer; 2010

[8] Davison K, Potter G, Evans J, Greene L, Hargis P, Corn C, et al. Growth, nutrient utilization, radiographic bone characteristics and postprandial thyroid hormone concentrations in weanling horses fed added dietary fat. Journal of Equine Veterinary Science. 1991;**11**(2):119-125

[9] Toft AD, Boon NA. Thyroid disease and the heart. Heart. 2000;**84**:455-460

[10] Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of

thyroid nodules detected at US: Society of radiologists in ultrasound consensus conference statement. Ultrasound Quarterly. 2006;**22**(4):231-238

[11] Gardner DG, Shoback D, ve Greenspan FS. Greenspan's Basic & Clinical Endocrinology. China: McGraw-Hill Medical; 2007

[12] Gharib H, Papini E, Paschke R, Duick D, Valcavi R, Hegedüs L, et al. American association of clinical endocrinologists, associazione medici endocrinologi, and european thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocrine Practice. 2010;**16**(Suppl. 1):1-43

[13] Goudreau E, Comtois R, Bayardelle P, Beauregard H, ve Larochelle D. Capnocytophaga ochracea and group F beta-hemolytic streptococcus suppurative thyroiditis. The Journal of Otolaryngology. 1986;**15**(1):59-61

[14] Vasudevan DM, Sreekumari S. Thyroid hormones. In: Textbook of Biochemistry. 4th ed. New Delhi: Jaypee; 2004

[15] White BA, Porterfield SP. The thyroid gland. In: White BA, Porterfield SP, editors. Endocrine and Reproductive Physiology. 4th ed. Philadelphia: Elsevier; 2013. pp. 129-147

[16] Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR. Thyroid hormones and skeletal muscle — New insights and potential implications. Nature Reviews. Endocrinology. 2014;**10**(4):206-214

[17] Oppenheimer JH, Schwartz HL, Lane JT, Thompson MP. Functional

*Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System DOI: http://dx.doi.org/10.5772/intechopen.109623*

relationship of thyroid hormoneinduced lipogenesis, lipolysis and thermogenesis in the rat. The Journal of Clinical Investigation. 1991;**87**(1):125-132

[18] Weintraub M, Grosskopf I, Trostanesky Y, Charach G, Rubinstein A, Stern N. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 1999;**84**(7):2532-2536

[19] Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews. 2008;**29**:76-131

[20] Jabbar A, Razvi S. Thyroid disease and vascular risk. Clinical Medicine (London, England). 2014;**14**(Suppl. 6): s29-s32

[21] Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nature Reviews. Cardiology. 2017;**14**:39-55

[22] Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Archives of Internal Medicine. 1988;**148**:626-631

[23] von Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R, Beyer J, et al. Cardiac arrhythmias and heart rate in hyperthyroidism. The American Journal of Cardiology. 1989;**63**:930-933

[24] Sandler B, Webb P, Apriletti JW, et al. Thyroxine-thyroid hormone receptor interactions. The Journal of Biological Chemistry. 2004;**279**:55801-55808

[25] Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Failure Reviews. 2010;**15**:125-132

[26] Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nature Reviews. Endocrinology. 2016;**12**:111-121

[27] Klein I. Chapter 81: Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease. 10th ed. Philadelphia, Pennsylvania: Elsevier; 2014. pp. 1793-1808

[28] Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, et al. Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovascular Research. 2010;**85**:560-570

[29] Papaioannou GI, Lagasse M, Mather JF, Thompson PD. Treating hypothyroidism improves endothelial function. Metabolism. 2004;**53**:278-279

[30] Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. The Journal of Clinical Endocrinology and Metabolism. 2003;**88**:3731-3737

[31] Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: Randomized, crossover trial. The Journal of Clinical Endocrinology and Metabolism. 2007;**92**:1715-1723

[32] Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. The New England Journal of Medicine. 1995;**333**:1522-1527

[33] Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with

chronic heart failure and lowT3 syndrome: A randomized, placebo-controlled study. The Journal of Clinical Endocrinology and Metabolism. 2008;**93**:1351-1358

[34] Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. European Journal of Internal Medicine. 2006;**17**:267-271

[35] de Castro AL, Fernandes RO, Ortiz VD, Campos C, Bonetto JH, Fernandes TR, et al. Thyroid hormones improve cardiac function and decrease expression of pro-apoptotic proteins in the heart of rats 14 days after infarction. Apoptosis. Feb 2016;**21**(2):184-194

[36] Li J, Donath S, Li Y, Qin D, Prabhakar BS, Li P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genetics. 2010;**6**:e1000795

[37] Forini F, Kusmic C, Nicolini G, et al. Triiodothyronine prevents cardiac ischemia/reperfusion mitochondrial impairment and cell loss by regulating miR30a/p53 axis. Endocrinology. 2014;**155**:4581-4590

[38] Pantos C, Mourouzis I, Dimopoulos A, et al. Enhanced tolerance of the rat myocardium to ischemia and reperfusion injury early after acute myocardial infarction. Basic Research in Cardiology. 2007;**102**:327-333

[39] Pantos C, Mourouzis I, Saranteas T, et al. Thyroid hormone improves postischaemic recovery of function while limiting apoptosis: A new therapeutic approach to support hemodynamics in the setting of ischaemia-reperfusion? Basic Research in Cardiology. 2009;**104**:69-77

[40] Danzi S, Klein I. Thyroid hormone and blood pressure regulation. Current Hypertension Reports. 2003;**5**:513-520

[41] Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC, Gammage MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart. 1996;**75**:363-368

[42] Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid. 1997;**7**:411-414

[43] Dernellis J, Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. American Heart Journal. 2002;**143**:718-724

[44] Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. Increased central arterial stiffness in hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 2002;**87**:4662-4666

[45] Taddei S, Caraccio N, Virdis A, et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto's thyroiditis. The Journal of Clinical Endocrinology and Metabolism. 2006;**91**:5076-5082

[46] Türemen EE, Çetinarslan B, Şahin T, Cantürk Z, Tarkun I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocrine Journal. 2011;**58**:349-354

[47] Marazuela M, Sánchez-Madrid F, Acevedo A, Larrañaga E, de Landázuri MO. Expression of vascular adhesion molecules on human endothelia in autoimmune thyroid disorders.

*Thyroid Hormones (T3 and T4) and Their Effects on the Cardiovascular System DOI: http://dx.doi.org/10.5772/intechopen.109623*

Clinical and Experimental Immunology. 1995;**102**:328-334

[48] Duntas LH. Thyroid disease and lipids. Thyroid. 2002;**12**:287-293

[49] Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 1998;**83**:1752-1755

[50] Costantini F, Pierdomenico SD, De Cesare D, et al. Effect of thyroid function on LDL oxidation. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;**18**:732-737

[51] Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid. 2000;**10**:803-808

[52] Martinez-Triguero ML, Hernández-Mijares A, Nguyen TT, et al. Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism. Mayo Clinic Proceedings. 1998;**73**:837-841

[53] Dörr M, Robinson DM, Wallaschofski H, et al. Low serum thyrotropin is associated with high plasma fibrinogen. The Journal of Clinical Endocrinology and Metabolism. 2006;**91**:530-534

[54] Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: Subclinical hyperthyroidism increases plasma factor X activity. Clinical Endocrinology. 2006;**64**:323-329

[55] Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet

plug formation in hyperthyroidism and hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 2007;**92**:3006-3012

[56] Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 2001;**86**:732-737

Section 3
